Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tafamidis

FDA-approved product (capsule, oral), marketed as Vyndamax, Vyndaqel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tafamidis
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • AL amyloidosis
  • Amyloidosis
  • Cardiomyopathy

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other nervous system drugs
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tafamidis in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tafamidis with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy

    NCT00694161 · start 2008-08

    Registered record
    Registry ID
    NCT00694161
    Conditions
    Cardiomyopathy
    Interventions
    Fx-1006A
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-08
    Completion
    2010-01
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiomyopathy
    InterventionFx-1006A
    PhasePhase 2
    Registry statusCompleted

  • An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy

    NCT00791492 · start 2008-07

    Registered record
    Registry ID
    NCT00791492
    Conditions
    Familial Amyloid Polyneuropathy; ATTR-PN
    Interventions
    Fx-1006A
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2010-10
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFamilial Amyloid Polyneuropathy; ATTR-PN
    InterventionFx-1006A
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis

    NCT00630864 · start 2008-06

    Registered record
    Registry ID
    NCT00630864
    Conditions
    Transthyretin-associated Amyloidosis With Polyneuropathy
    Interventions
    Fx-1006A
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-06
    Completion
    2010-01
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin-associated Amyloidosis With Polyneuropathy
    InterventionFx-1006A
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis

    NCT00409175 · start 2007-01

    Registered record
    Registry ID
    NCT00409175
    Conditions
    Familial Amyloid Polyneuropathy
    Interventions
    Fx-1006A; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-01
    Completion
    2009-05
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFamilial Amyloid Polyneuropathy
    InterventionFx-1006A; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)

    NCT04776824 · start 2001-02-22

    Registered record
    Registry ID
    NCT04776824
    Conditions
    Amyloid Cardiomyopathy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2001-02-22
    Completion
    2031-05-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloid Cardiomyopathy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting